The latest price target for Cidara Therapeutics (NASDAQ:CDTX) was reported by HC Wainwright & Co. on September 16, 2024. The analyst firm set a price target for $24.00 expecting CDTX to rise to within 12 months (a possible 112.95% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for Cidara Therapeutics (NASDAQ:CDTX) was provided by HC Wainwright & Co., and Cidara Therapeutics reiterated their buy rating.

The last upgrade for Cidara Therapeutics Inc happened on August 14, 2024 when HC Wainwright & Co. raised their price target to $24. HC Wainwright & Co. previously had a neutral for Cidara Therapeutics Inc.

There is no last downgrade for Cidara Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cidara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cidara Therapeutics was filed on September 16, 2024 so you should expect the next rating to be made available sometime around September 16, 2025.

While ratings are subjective and will change, the latest Cidara Therapeutics (CDTX) rating was a reiterated with a price target of $24.00 to $24.00. The current price Cidara Therapeutics (CDTX) is trading at is $11.27, which is out of the analyst’s predicted range.